Sung Yoon Park1, Young Taik Oh2,3, Dae Chul Jung1, Nam Hoon Cho4, Young Deuk Choi5, Koon Ho Rha5, Sung Joon Hong5. 1. Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea. 2. Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea. oytaik@yuhs.ac. 3. Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. oytaik@yuhs.ac. 4. Department of Pathology, Yonsei University College of Medicine, Seoul, Korea. 5. Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
Abstract
OBJECTIVES: To determine whether the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) helps predict biochemical recurrence (BCR) after radical prostatectomy for prostate cancer (PCa). METHODS: We included 158 patients with PCa who underwent magnetic resonance imaging (MRI) and radical prostatectomy (RP). Clinical (prostate-specific antigen, greatest percentage of core, and percentage of positive core number), PI-RADSv2 score on MRI, and surgical parameters (Gleason score, extracapsular extension, seminal vesicle invasion, and tumour volume) were investigated. Univariate and multivariate analyses using Cox's proportional hazards model were performed to assess parameters predictive of BCR (two consecutive prostate specific antigens ≥0.2 ng/ml). Kaplan-Meier survival curves were analyzed. RESULTS: The rate of BCR was 13.3 % (21/158) after surgery (median follow-up, 25 months; range, 12-36). No subject with a PI-RADS score <4 had BCR. In univariate analysis, all parameters were significant for BCR (p < 0.05), except seminal vesicle invasion (p = 0.254). Meanwhile, PI-RADS score was the only independent parameter for BCR in multivariate analysis (p < 0.05). Two-year, BCR-free survival post-RP was significantly lower for PI-RADS ≥4 (84.7-85.5 %) than for PI-RADS <4 (100 %; p < 0.05). CONCLUSION: As a preoperative imaging tool, PI-RADSv2 may be useful to predict BCR after radical prostatectomy for PCa. KEY POINTS: • No subject with PI-RADS <4 had BCR after RP • PI-RADSv2 was the only predictor of BCR in multivariate analysis • Two-year, BCR-free survival following RP was lower for PI-RADS≥4 than for PI-RADS<4 • Inter-rater agreement was good for PI-RADS ≥4 or not.
OBJECTIVES: To determine whether the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) helps predict biochemical recurrence (BCR) after radical prostatectomy for prostate cancer (PCa). METHODS: We included 158 patients with PCa who underwent magnetic resonance imaging (MRI) and radical prostatectomy (RP). Clinical (prostate-specific antigen, greatest percentage of core, and percentage of positive core number), PI-RADSv2 score on MRI, and surgical parameters (Gleason score, extracapsular extension, seminal vesicle invasion, and tumour volume) were investigated. Univariate and multivariate analyses using Cox's proportional hazards model were performed to assess parameters predictive of BCR (two consecutive prostate specific antigens ≥0.2 ng/ml). Kaplan-Meier survival curves were analyzed. RESULTS: The rate of BCR was 13.3 % (21/158) after surgery (median follow-up, 25 months; range, 12-36). No subject with a PI-RADS score <4 had BCR. In univariate analysis, all parameters were significant for BCR (p < 0.05), except seminal vesicle invasion (p = 0.254). Meanwhile, PI-RADS score was the only independent parameter for BCR in multivariate analysis (p < 0.05). Two-year, BCR-free survival post-RP was significantly lower for PI-RADS ≥4 (84.7-85.5 %) than for PI-RADS <4 (100 %; p < 0.05). CONCLUSION: As a preoperative imaging tool, PI-RADSv2 may be useful to predict BCR after radical prostatectomy for PCa. KEY POINTS: • No subject with PI-RADS <4 had BCR after RP • PI-RADSv2 was the only predictor of BCR in multivariate analysis • Two-year, BCR-free survival following RP was lower for PI-RADS≥4 than for PI-RADS<4 • Inter-rater agreement was good for PI-RADS ≥4 or not.
Authors: Ali Sami Kıvrak; Yahya Paksoy; Cengiz Erol; Mustafa Koplay; Seda Özbek; Fatih Kara Journal: Diagn Interv Radiol Date: 2013 Nov-Dec Impact factor: 2.630
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Mark K Buyyounouski; Tom Pickles; Larry L Kestin; Roger Allison; Scott G Williams Journal: J Clin Oncol Date: 2012-04-16 Impact factor: 44.544
Authors: Caroline M A Hoeks; Diederik M Somford; Inge M van Oort; Henk Vergunst; Jorg R Oddens; Geert A Smits; Monique J Roobol; Meelan Bul; Thomas Hambrock; J Alfred Witjes; Jurgen J Fütterer; Christina A Hulsbergen-van de Kaa; Jelle O Barentsz Journal: Invest Radiol Date: 2014-03 Impact factor: 6.016
Authors: Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto Journal: Future Oncol Date: 2016-07-12 Impact factor: 3.404
Authors: Andrei S Purysko; Cristina Magi-Galluzzi; Omar Y Mian; Sarah Sittenfeld; Elai Davicioni; Marguerite du Plessis; Christine Buerki; Jennifer Bullen; Lin Li; Anant Madabhushi; Andrew Stephenson; Eric A Klein Journal: Eur Radiol Date: 2019-03-07 Impact factor: 5.315
Authors: O Solyanik; B Schlenker; C Gratzke; B Ertl-Wagner; D A Clevert; C Stief; J Ricke; D Nörenberg Journal: Urologe A Date: 2017-11 Impact factor: 0.639
Authors: Naomi Morka; Benjamin S Simpson; Rhys Ball; Alex Freeman; Alex Kirkham; Daniel Kelly; Hayley C Whitaker; Mark Emberton; Joseph M Norris Journal: BMJ Open Date: 2021-05-05 Impact factor: 2.692
Authors: Lars A R Reisæter; Jurgen J Fütterer; Are Losnegård; Yngve Nygård; Jan Monssen; Karsten Gravdal; Ole J Halvorsen; Lars A Akslen; Martin Biermann; Svein Haukaas; Jarle Rørvik; Christian Beisland Journal: Eur Radiol Date: 2017-10-06 Impact factor: 5.315